01513 LIVZON PHARMA
- 27.400
- +0.300+1.11%
LIVZON PHARMA News
LIVZON PHARMA (01513.HK) spent 5.5 million yuan to repurchase 0.144 million shares on December 27.
On December 27, Glory Link announced that LIVZON PHARMA (01513.HK) spent RMB 5.5 million to repurchase 0.144 million shares, with the repurchase price per share ranging from 37.91 to 38.23 yuan.
December 24 repurchase collection | TENCENT, HSBC Holdings and others have repurchased, with TENCENT spending 0.503 billion HKD.
According to a disclosure from HKEX on December 27, TENCENT (00700.HK), HSBC Holdings (00005.HK), and others repurchased shares. ① TENCENT (00700.HK) repurchased 1.2 million shares of common stock on December 24, involving an amount of 0.503 billion Hong Kong dollars, with a repurchase price ranging from 421.4 to 417.8 Hong Kong dollars per share. Since the buyback authorization resolution, the total number of repurchased securities is 0.226 billion shares, accounting for 2.395% of the number of issued shares at the time the ordinary resolution was passed. ② HSBC Holdings (00005.HK)
LIVZON PHARMA (01513.HK) spent 5.4987 million yuan to repurchase 0.1453 million shares on December 26.
On December 26th, Grapevine reported that LIVZON PHARMA (01513.HK) announced a buyback of 0.1453 million shares at a cost of 5.4987 million yuan, with a buyback price per share ranging from 37.72 to 38 yuan.
LIVZON PHARMA (01513.HK) spent 5.4997 million yuan to repurchase 0.1457 million shares on December 25.
On December 26, Gelonghui reported that LIVZON PHARMA (01513.HK) announced it spent 5.4997 million yuan on December 25 to repurchase 0.1457 million shares, at a repurchase price of 37.5-37.97 yuan per share.
Livzon Pharmaceutical Group Inc. (000513.SZ): Spent 5.4997 million yuan to repurchase 0.1457 million A-shares.
On December 25, Glonghui reported that Livzon Pharmaceutical Group Inc. (000513.SZ) announced the repurchase of 0.1457 million shares of its A-shares for the first time through centralized bidding on December 25, 2024, accounting for 0.02% of the company's total share capital. The highest purchase price was 37.97 yuan per share, and the lowest price was 37.50 yuan per share, with a total amount of funds used being 5.4997 million yuan (excluding transaction fees).
Express News | Overview of A-share Share Buyback: 27 companies have disclosed their buyback progress.
Express News | The latest adjustments by foreign capital: BNP Paribas slightly increased its Shareholding in Kweichow Moutai, while the Abu Dhabi Investment Authority reduced its Shareholding in Livzon Pharmaceutical Group Inc., and United Bankshares increased its Share
Express News | State Council meeting: Deploy measures to deepen the reform of Pharmaceutical and medical instruments regulatory system to promote high-quality development of the pharmaceutical industry.
Express News | Livzon Pharmaceutical Group Inc.: Plans to buy back company shares worth 0.6 billion to 1 billion yuan.
LIVZON PHARMA (01513.HK) spent 4.1397 million HKD to repurchase 0.1527 million shares on December 24.
Gelonghui, December 24丨LIVZON PHARMA (01513.HK) announced that on December 24, it spent 4.1397 million Hong Kong dollars to repurchase 0.1527 million shares, with a repurchase price per share of 26.85-27.2 Hong Kong dollars.
December 23 repurchase collection | TENCENT, HSBC Holdings, and others have successively repurchased, among which TENCENT spent 0.704 billion HKD.
According to a disclosure by HKEX on December 24, TENCENT (00700.HK) and HSBC Holdings (00005.HK) have repurchased shares. ① TENCENT (00700.HK) repurchased 1.67 million ordinary shares on December 23, involving an amount of 0.704 billion Hong Kong dollars, with a repurchase price ranging from 430.6 HKD to 416.4 HKD per share. Since the repurchase authorization resolution, the cumulative number of securities repurchased has been 0.224 billion shares, accounting for 2.382% of the total issued shares at the time of approval of the ordinary resolution. ② HSBC Holdings (00005.HK)
LIVZON PHARMA (01513.HK) spent 5.66 million HKD to repurchase 0.211 million shares on December 23.
Gelonghui, December 23 - LIVZON PHARMA (01513.HK) announced that on December 23, it spent 5.66 million Hong Kong dollars to repurchase 0.211 million shares.
Nomura lists the list of Chinese stocks that are expected to "continue to outperform" (table).
Nomura published a report on the Asia (excluding Japan) stock market, listing Chinese stocks that are "Consistent Outperformers," with criteria including a listing period of at least six years, daily average trading volume exceeding 0.5 million USD, relative performance superior to the benchmark since 2015/listing date, and a market cap exceeding 0.5 billion USD.
Repurchase summary on December 20 | TENCENT, HSBC Holdings and others have repurchased shares, with TENCENT spending 0.703 billion HKD.
According to a document disclosed by HKEX on December 23, both TENCENT (00700.HK) and HSBC Holdings (00005.HK) have repurchased shares. ① TENCENT (00700.HK) repurchased 1.65 million ordinary shares on December 20, involving an amount of 0.703 billion HKD, with a repurchase price ranging from 428.2 HKD to 414.2 HKD per share. Since the repurchase authorization resolution, the total number of shares repurchased is 0.223 billion shares, accounting for 2.365% of the number of shares issued at the time the ordinary resolution was passed. ② HSBC Holdings (00005.HK)
LIVZON PHARMA (01513.HK) spent 5.238 million Hong Kong dollars to buy back 0.195 million shares on December 20.
On December 20, Glonhui reported that LIVZON PHARMA (01513.HK) announced it repurchased 195,000 shares for HKD 5.238 million.
Share repurchase collection on December 19 | TENCENT, AIA and others have repurchased shares, among which TENCENT spent 0.703 billion HKD.
According to the documents disclosed by HKEX on December 20, TENCENT (00700.HK), AIA (01299.HK), and others have repurchased shares. ① TENCENT (00700.HK) repurchased 1.72 million ordinary shares on December 19, involving an amount of 0.703 billion HKD, with the repurchase price ranging from 421.8 HKD to 401.4 HKD per share. Since the repurchase authorization resolution, the cumulative number of repurchased securities is 0.221 billion shares, accounting for 2.347% of the number of shares issued when the ordinary resolution was passed. ② AIA (01299.HK)
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
LIVZON PHARMA (01513.HK) spent HKD 2.712 million to repurchase 0.1 million shares on December 19.
Gelonghui reported on December 19 that LIVZON PHARMA (01513.HK) announced the repurchase of 100,000 shares at a cost of 2.712 million Hong Kong dollars on December 19.
December 18 repurchase collection | TENCENT, ANTA SPORTS and others have repurchased, among which TENCENT spent 0.703 billion Hong Kong dollars.
According to a document disclosed by HKEX on December 19, TENCENT (00700.HK), ANTA SPORTS (02020.HK), and others have repurchased shares. ① TENCENT (00700.HK) repurchased 1.73 million ordinary shares on December 18, involving an amount of 0.703 billion HKD, with a repurchase price ranging from 406 HKD to 405.2 HKD per share. Since the repurchase authorization resolution, the cumulative number of securities repurchased has been 0.219 billion shares, accounting for 2.329% of the number of shares issued at the time of the ordinary resolution's approval. ② ANTA SPORTS (02020.HK) repurchased 1
On December 18, LIVZON PHARMA (01513) spent HKD 2.6035 million to buy back 0.0965 million shares.
LIVZON PHARMA (01513) announced that it will spend 2.6035 million Hong Kong dollars to repurchase on December 18, 2024...
No Data